Our care team explains all financial aspects, ensuring there are no surprises and that you understand all cost-saving options, like manufacturer savings and copay assistance programs
management may include saliva stimulants, topical therapies, immunomodulatory care, and coordinated rheumatology and dental follow-up
Your provider may suggest a follow-up visit or order lab tests first to be extra safe
Legal and regulatory considerations for bulk peptide purchases Navigating the legal landscape around bulk peptide purchasing is essential for researchers who want to avoid regulatory complications
Michigan watched its own GLP-1 costs rocket from $8 million to $300 million in just three years
Novo Nordisk takes PADE reporting requirements seriously and we plan to address the requests in the Warning Letter expeditiously and holistically, Anna Windle, head of clinical development, medical and regulatory affairs at Novo Nordisk U.S., said in the statement